Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2975969 | 0.92 | GPR132 (0.43) | HPGDALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2975296 | 0.91 | RIPK1 (0.47) | HPGDALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2970729 | 0.91 | HPGD (0.47) | HPGDALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2973781 | 0.89 | ALOX5 (0.47) | HPGDALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL13202025 | 0.89 | MRGPRX4 (0.53) | HPGDSMN1; SMN2MRGPRX4CYP19A1CYP11B1 | |
| SCHEMBL2975358 | 0.87 | MRGPRX4 (0.51) | HPGDMRGPRX4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL4068787 | 0.87 | MRGPRX4 (0.40) | HPGDALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2964769 | 0.86 | SMN1; SMN2 (0.53) | HPGDALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2976410 | 0.86 | HPGD (0.45) | HPGDKCNH2EPHX2 | |
| SCHEMBL2962847 | 0.85 | HPGD (0.47) | HPGDKCNH2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767673-B2 | N-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | claimed |
| EP-1658289-B1 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARM INC (US) | 2009-03-18 | — | — | EP | claimed |
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | claimed |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | CASTELHANO ARLINDO L | 2008-09-11 | — | — | US | claimed |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | CASTELHANO ARLINDO L | 2006-02-16 | — | — | US | claimed |
| US-7767673-B2 | N-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1658289-B1 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARM INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-7442709-B2 | N3-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | CASTELHANO ARLINDO L | 2008-09-11 | — | — | US | disclosed |
| EP-1658289-A2 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | CASTELHANO ARLINDO L | 2006-02-16 | — | — | US | disclosed |
| WO-2005021544-A2 | N3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | KIT, ABL1, CHUK | HPGD 666/4885ALDH1A1 379/4885CYP2C9 735/4885 |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | KIT, ABL1, CHUK | HPGD 1281/4885ALDH1A1 520/4885CYP2C9 1017/4885 |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | KIT, ABL1, CHUK | HPGD 1281/4885ALDH1A1 520/4885CYP2C9 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.